Yu-Hui Liu1, Yang Chen1, Qing-Hua Wang1, Ling-Ru Wang1, Li Jiang1, Ying Yang1, Xian Chen2, Ying Li3, Yuan Cen4, Cheng Xu5, Jie Zhu1, Wei Li1, Ye-Ran Wang1, Li-Li Zhang1, Juan Liu1, Zhi-Qiang Xu1, Yan-Jiang Wang1. 1. Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China. 2. Department of Anaesthesiology, Daping Hospital, Third Military Medical University, Chongqing, China. 3. Department of Ophthalmology, Daping Hospital, Third Military Medical University, Chongqing, China. 4. Department of Orthopedics, Daping Hospital, Third Military Medical University, Chongqing, China. 5. Department of Oncology, General Hospital of the Central Theatre Command of the People's Liberation Army, Wuhan, China.
Abstract
Importance: Determining the long-term impact of COVID-19 on cognition is important to inform immediate steps in COVID-19 research and health policy. Objective: To investigate the 1-year trajectory of cognitive changes in older COVID-19 survivors. Design, Setting, and Participants: This cohort study recruited 3233 COVID-19 survivors 60 years and older who were discharged from 3 COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020. Their uninfected spouses (N = 466) were recruited as a control population. Participants with preinfection cognitive impairment, a concomitant neurological disorder, or a family history of dementia were excluded, as well as those with severe cardiac, hepatic, or kidney disease or any kind of tumor. Follow-up monitoring cognitive functioning and decline took place at 6 and 12 months. A total of 1438 COVID-19 survivors and 438 control individuals were included in the final follow-up. COVID-19 was categorized as severe or nonsevere following the American Thoracic Society guidelines. Main Outcomes and Measures: The main outcome was change in cognition 1 year after patient discharge. Cognitive changes during the first and second 6-month follow-up periods were assessed using the Informant Questionnaire on Cognitive Decline in the Elderly and the Telephone Interview of Cognitive Status-40, respectively. Based on the cognitive changes observed during the 2 periods, cognitive trajectories were classified into 4 categories: stable cognition, early-onset cognitive decline, late-onset cognitive decline, and progressive cognitive decline. Multinomial and conditional logistical regression models were used to identify factors associated with risk of cognitive decline. Results: Among the 3233 COVID-19 survivors and 1317 uninfected spouses screened, 1438 participants who were treated for COVID-19 (691 male [48.05%] and 747 female [51.95%]; median [IQR] age, 69 [66-74] years) and 438 uninfected control individuals (222 male [50.68%] and 216 female [49.32%]; median [IQR] age, 67 [66-74] years) completed the 12-month follow-up. The incidence of cognitive impairment in survivors 12 months after discharge was 12.45%. Individuals with severe cases had lower Telephone Interview of Cognitive Status-40 scores than those with nonsevere cases and control individuals at 12 months (median [IQR]: severe, 22.50 [16.00-28.00]; nonsevere, 30.00 [26.00-33.00]; control, 31.00 [26.00-33.00]). Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20), late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03), and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51), while nonsevere COVID-19 was associated with a higher risk of early-onset cognitive decline (OR, 1.71; 95% CI, 1.30-2.27) when adjusting for age, sex, education level, body mass index, and comorbidities. Conclusions and Relevance: In this cohort study, COVID-19 survival was associated with an increase in risk of longitudinal cognitive decline, highlighting the importance of immediate measures to deal with this challenge.
Importance: Determining the long-term impact of COVID-19 on cognition is important to inform immediate steps in COVID-19 research and health policy. Objective: To investigate the 1-year trajectory of cognitive changes in older COVID-19 survivors. Design, Setting, and Participants: This cohort study recruited 3233 COVID-19 survivors 60 years and older who were discharged from 3 COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020. Their uninfected spouses (N = 466) were recruited as a control population. Participants with preinfection cognitive impairment, a concomitant neurological disorder, or a family history of dementia were excluded, as well as those with severe cardiac, hepatic, or kidney disease or any kind of tumor. Follow-up monitoring cognitive functioning and decline took place at 6 and 12 months. A total of 1438 COVID-19 survivors and 438 control individuals were included in the final follow-up. COVID-19 was categorized as severe or nonsevere following the American Thoracic Society guidelines. Main Outcomes and Measures: The main outcome was change in cognition 1 year after patient discharge. Cognitive changes during the first and second 6-month follow-up periods were assessed using the Informant Questionnaire on Cognitive Decline in the Elderly and the Telephone Interview of Cognitive Status-40, respectively. Based on the cognitive changes observed during the 2 periods, cognitive trajectories were classified into 4 categories: stable cognition, early-onset cognitive decline, late-onset cognitive decline, and progressive cognitive decline. Multinomial and conditional logistical regression models were used to identify factors associated with risk of cognitive decline. Results: Among the 3233 COVID-19 survivors and 1317 uninfected spouses screened, 1438 participants who were treated for COVID-19 (691 male [48.05%] and 747 female [51.95%]; median [IQR] age, 69 [66-74] years) and 438 uninfected control individuals (222 male [50.68%] and 216 female [49.32%]; median [IQR] age, 67 [66-74] years) completed the 12-month follow-up. The incidence of cognitive impairment in survivors 12 months after discharge was 12.45%. Individuals with severe cases had lower Telephone Interview of Cognitive Status-40 scores than those with nonsevere cases and control individuals at 12 months (median [IQR]: severe, 22.50 [16.00-28.00]; nonsevere, 30.00 [26.00-33.00]; control, 31.00 [26.00-33.00]). Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20), late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03), and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51), while nonsevere COVID-19 was associated with a higher risk of early-onset cognitive decline (OR, 1.71; 95% CI, 1.30-2.27) when adjusting for age, sex, education level, body mass index, and comorbidities. Conclusions and Relevance: In this cohort study, COVID-19 survival was associated with an increase in risk of longitudinal cognitive decline, highlighting the importance of immediate measures to deal with this challenge.
Authors: Berislav V Zlokovic; Rebecca F Gottesman; Kenneth E Bernstein; Sudha Seshadri; Ann McKee; Heather Snyder; Steven M Greenberg; Kristine Yaffe; Chris B Schaffer; Chun Yuan; Timothy M Hughes; Mat J Daemen; Jeff D Williamson; Hector M González; Julie Schneider; Cheryl L Wellington; Zvonimir S Katusic; Luke Stoeckel; James I Koenig; Roderick A Corriveau; Lawrence Fine; Zorina S Galis; Jared Reis; Jacqueline D Wright; Jue Chen Journal: Alzheimers Dement Date: 2020-10-08 Impact factor: 21.566
Authors: V C T Mok; A Wong; W W M Lam; Y H Fan; W K Tang; T Kwok; A C F Hui; K S Wong Journal: J Neurol Neurosurg Psychiatry Date: 2004-04 Impact factor: 10.154
Authors: Max Augustin; Philipp Schommers; Melanie Stecher; Felix Dewald; Lutz Gieselmann; Henning Gruell; Carola Horn; Kanika Vanshylla; Veronica Di Cristanziano; Luise Osebold; Maria Roventa; Toqeer Riaz; Nikolai Tschernoster; Janine Altmueller; Leonard Rose; Susanne Salomon; Vanessa Priesner; Jan Christoffer Luers; Christian Albus; Stephan Rosenkranz; Birgit Gathof; Gerd Fätkenheuer; Michael Hallek; Florian Klein; Isabelle Suárez; Clara Lehmann Journal: Lancet Reg Health Eur Date: 2021-05-18
Authors: Jonas A Hosp; Andrea Dressing; Ganna Blazhenets; Tobias Bormann; Alexander Rau; Marius Schwabenland; Johannes Thurow; Dirk Wagner; Cornelius Waller; Wolf D Niesen; Lars Frings; Horst Urbach; Marco Prinz; Cornelius Weiller; Nils Schroeter; Philipp T Meyer Journal: Brain Date: 2021-04-03 Impact factor: 13.501
Authors: Alberto Mantovani; Maria Concetta Morrone; Carlo Patrono; M Gabriella Santoro; Stefano Schiaffino; Giuseppe Remuzzi; Giovanni Bussolati Journal: Cell Death Differ Date: 2022-09-07 Impact factor: 12.067